Phase 1b/2 NORSE Study @MDAndersonNews

Arlene Siefker-Radtke, MD of @MDAndersonNews discusses the phase 1b/2 NORSE study on the treatment of metastatic urothelial carcinoma in patients with select FGFR alterations.

Phase 1b/2 NORSE Study @MDAndersonNews

MOASC Awards $25,000 Research Grant from AVEO Oncology to Dr. Peter Zang, MD of City of Hope 2025 Cary Presant, MD Investigator Award

MRI’s Role in Prostate Cancer Diagnosis, a 3-Year Study Breakthrough

Overview of SYNC-T Technology from Syncromune in Prostate Cancer Treatment – Charles Link, MD

Phase 1b/2 NORSE Study @MDAndersonNews

Related Posts

MOASC Awards $25,000 Research Grant from AVEO Oncology to Dr. Peter Zang, MD of City of Hope 2025 Cary Presant, MD Investigator Award

MRI’s Role in Prostate Cancer Diagnosis, a 3-Year Study Breakthrough

Overview of SYNC-T Technology from Syncromune in Prostate Cancer Treatment – Charles Link, MD